GROWTH FACTORS DECREASE IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE (AD): POTENTIAL CORRECTION WITH DEHYDROEPIANDROSTERONE-SULPHATE (DHEAS)

https://doi.org/10.1016/j.archger.2009.09.027Get rights and content

Abstract

The integrity of neuroprotection is an important component against the development of cognitive disorders and AD. Within this context, DHEAS would seem to have some positive metabolic and endocrine effects to delay brain aging by recovering the impairment of neuroprotective growth factors. In the present study we measured by ELISA the secretion of insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), and transforming growth factor-β1 (TGFβ1) in the supernatants of cultured circulating peripheral blood mononuclear cells (PBMC) from which natural killer cells (NK) were separated (PBMC-NK) (pg/ml/7.75 × 106 cells) in healthy subjects and in age-matched patients with mild to moderate AD. The growth factors were measured in spontaneous conditions and after stimulation with growth hormone (GH) 1 μg/ml (IGF-1), lipopolysaccharide (LPS) 1 μg/ml (VEGF) and glucose 10 μM (TGF(β1). AD group demonstrated at baseline a severe reduction of IGF-1 (3.7 + 1.2 pg/ml after GH), VEGF (63 ± 18 pg/ml spontaneous and 210 ± 65 pg/ml after LPS) and TGF(β1 (33 ± 10 pg/ml spontaneous and 75 ± 12 pg/ml after glucose) secretions compared to healthy elderly subjects (IGF-1, 9.5 ± 2.8 pg/ml after GH, p < 0.001; VEGF, 117 ± 38 pg/ml spontaneous, p < 0.001 and 690 ± 120 pg/ml after LPS, p < 0.001; and TGF(β1, 73 ± 21 pg/ml spontaneous, p < 0.001 and 169 ± 53 pg/ml after glucose, p < 0.001). Significant positive correlations between IGF-1 and VEGF concentrations were found both in healthy subjects (r = 0.87, p < 0.001) and in AD subjects (r = 0.87, p < 0.001). The co-incubation of NK cells with DHEAS (106 M/ml/cells) significantly increase IGF-1, VEGF and TGF (β1 production, reaching in AD group the normal concentrations found in healthy subjects (IGF-1, 7.9 + 2.4 pg/ml after GH; VEGF, 105 ± 31 pg/ml spontaneous and 670 ± 112 pg/ml after LPS; and TGFfβ1, 68 ± 18 pg/ml spontaneous and 155 ± 48 pg/ml after glucose). These data suggested that DHEAS is able to increase the immunoendocrine production of neuroprotective growth factors, which is reduced in AD subjects, so suggesting a new approach in the treatment of dementia.

References (30)

  • APA (American Psychiatric Association), (1994): Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). APA...
  • J. Blass

    The mitochondrial spiral. An adequate cause of dementia in Alzheimer's disease

    Ann. N. Y. Acad. Sci.

    (2000)
  • A. Boyum

    Isolation of mononuclear cells and granulocytes from human blood.

    Scand. Clin. Lab. Invest, Suppl.

    (1990)
  • G.P. Ceda et al.

    Clinical implications of the reduced activity of the GH-IGF-1 axis in older men

    J. Endocrinol. Investig.

    (2005)
  • S. Croll et al.

    Vascular endothelial growth factor (VEGF) in seizures: a double edged sword?

    Adv. Exp. Med. Biol.

    (2004)
  • Cited by (27)

    • Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target

      2018, Pharmacological Research
      Citation Excerpt :

      Intranasal administration of TGF-β1, before i.c.v. Aβ(1-42) injection, prevented Aβ-induced increases in microglia-derived proinflammatory mediators (TNF-α, IL-1β and iNOS), thereby preventing amyloid-related neurodegeneration [118]. Coming back to MCI and AD patients, several studies have found a significant decrease in the plasma levels of the active (25 kDa) and inactive (50 kDa) forms of TGF-β1 in AD patients [140–142], as well as a reduced secretion of TGF-β1 from circulating peripheral blood mononuclear cells [143]. Interestingly, the deficit of TGF-β1 has been detected in the early phase of AD (preclinical AD) and, in particular, in amnestic MCI patients [144].

    • Steroid sulfatase inhibitor DU-14 protects spatial memory and synaptic plasticity from disruption by amyloid β protein in male rats

      2016, Hormones and Behavior
      Citation Excerpt :

      The mechanistic pathway that underlying the behavioral and electrophysiological effects of DU-14 is closely associated with the increased DHEAS. According to previous studies, up-regulation of DHEAS in the brain could: 1) block Aβ1–42 induced intracellular calcium overload (Kato-Negishi and Kawahara, 2008); 2) increase the production of growth factors (Luppi et al., 2009) and enhance brain cholinergic function (Dong and Zheng, 2012); 3) play an immunomodulatory role on NK functional activity in physiological aging and AD (Solerte et al., 1999); 4) have an antiglucocorticoid activity and neuroprotective effects, while its levels decreased in AD (Murialdo et al., 2001); 5) prevent the cells from entering late apoptosis and necrosis and stimulate neurite outgrowth per se (El Bitar et al., 2014); 6) protect hippocampal neurons against glutamate through elevating a kappaB-dependent transcription factor activity (Leskiewicz et al., 2008; Mao and Barger, 1998). Of course, a further investigation on the effects of DU-14 and its mechanisms in AD transgenic animals or AD patients would be urgently required in the future.

    • DHEA and cognitive function in the elderly

      2015, Journal of Steroid Biochemistry and Molecular Biology
    • Daily stressors and adult day service use by family caregivers: Effects on depressive symptoms, positive mood, and dehydroepiandrosterone-sulfate

      2014, American Journal of Geriatric Psychiatry
      Citation Excerpt :

      In turn, low levels of DHEA-S among older people have been linked to cancer, insulin resistance, cardiovascular disease, and immune system deficiencies.9,21 Although acute stress typically leads to increases in DHEA-S, prolonged exposure to stressors attenuates DHEA-S levels, thereby reducing its health protective effects.8,20 DHEA-S levels also decrease with age.10

    • VEGF plasma level variations in duloxetine-treated patients with major depression

      2013, Journal of Affective Disorders
      Citation Excerpt :

      There is strong association between depression (or other CNS pathologies such as Alzheimer's disease) and cardiovascular disease, suggesting a possible role of neurovascular unit abnormalities, possibly characterized by endothelial degenerations, capillary density changes and neuroinflammation (Fioravanzo et al., 2010; Taylor et al., 2013; Warner-Schmidt and Duman, 2008). A decrease in VEGF levels was observed in Alzheimer's disease, schizophrenia and autism (Emanuele et al., 2010; Fulzele and Pillai, 2009; Luppi et al., 2009), while an increase in VEGF levels was detected during acute manic episodes, in occurrences of prolonged psychosocial stress and anxiety conditions (Asberg et al., 2009; Kwon et al., 2011; Lee and Kim, 2012). A number of treatments have been shown to affect VEGF signaling.

    View all citing articles on Scopus
    View full text